1. Home
  2. SY vs CHRS Comparison

SY vs CHRS Comparison

Compare SY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo So-Young International Inc. American Depository Shares

SY

So-Young International Inc. American Depository Shares

HOLD

Current Price

$1.93

Market Cap

272.8M

Sector

Technology

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.46

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SY
CHRS
Founded
2013
2010
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.8M
296.8M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
SY
CHRS
Price
$1.93
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.50
$5.51
AVG Volume (30 Days)
860.8K
1.4M
Earning Date
05-15-2026
05-07-2026
Dividend Yield
0.91%
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.64
$73.08
Revenue Next Year
$30.63
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.72
52 Week High
$6.28
$2.62

Technical Indicators

Market Signals
Indicator
SY
CHRS
Relative Strength Index (RSI) 29.52 38.86
Support Level $1.86 $1.37
Resistance Level $3.34 $1.75
Average True Range (ATR) 0.21 0.08
MACD -0.05 -0.01
Stochastic Oscillator 5.88 1.75

Price Performance

Historical Comparison
SY
CHRS

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: